What is Talphera's gross profit margin?

What does Talphera do and what are its main business segments?

What is Talphera's latest dividend and current dividend yield?

What guidance did Talphera's management provide for the next earnings period?

What is the market's earnings forecast for Talphera next quarter?

What were the key takeaways from Talphera's earnings call?

What factors drove the changes in Talphera's revenue and profit?

Did Talphera beat or miss consensus estimates last quarter?

- **NEPHRO Study**: Delays push completion to H1 2026; 2/6 new sites activated with similar enrollment rates.
- **FDA Process**: Conditional approval for compassionate use in specific patient populations.
- **Capital**: $21.3M cash, with sufficient funding through 2026.
- **Regulatory**: Breakthrough designation maintains efficient engagement.
- **Commercial Readiness**: Anticipated PMA approval in H2 2026.

**【CEO & Clinical Study Updates】**
- The company has completed the first closing of $17M financing, including $5M strategic investment from CorMedix and $12M institutional investors. 
- NEPHRO study enrollment delayed to H1 2026 due to site activation delays, with 2 of 6 new sites activated, and remaining 4 under process.
- FDA approved compassionate use IDE submission for specific CRRT patients.
- Anticipated PMA approval in late 2026, with sufficient capital through 2026.

**【CFO Financial Update】**
- Cash balance $21.3M as of Q3 2025, with reduced operating expenses to $14-15M for 2025.
- Conditional tranches contingent on regulatory approvals and stock price thresholds.

**【Q&A Highlights】**
- New target sites demonstrate similar enrollment rates to existing sites, no material impact.
- VA site delays due to personnel cuts, but not impacting current operations.

**【Risk Mitigation】**
- FDA breakthrough designation, efficient regulatory engagement, and nafamostat's 30+ year safety profile.

Key enrollment site activation timelines and commercial readiness.

Talphera, Inc. (TLPH) Q3 2025 Earnings Call Transcript

- **NEPHRO Study Milestone Progress**: 15 patients enrolled in 6 weeks, targeting 70 by year-end with 6 new sites.
- **Cost Efficiency**: 2025 OpEx reduced to $16-17M, Q2 expenses down 14% YoY.
- **Strategic Enrollment Success**: 90% of enrollments from new nephrologist-led sites, 2 of 6 new sites activated.
- **Market Opportunity**: Growing demand for nafamostat amid heparin/citrate shortages, with compassionate use IDE discussions underway.

**【CEO Summary Section】**
- NEPHRO study enrollment accelerated with 15 patients enrolled since May, doubling previous rates. Restructured to 70-patient target from 166, focusing on nephrologist-led medical ICU sites. 6 new sites expected to activate by Q3 end, aiming for completion by year-end.
- Nafamostat's potential as FDA-approved regional anticoagulant for CRRT highlighted, with strong interest from institutions facing heparin/citrate shortages.

**【CMO Commentary】**
- 3 new profile sites contributed 90% of 15 enrollments, validating strategy. 6 additional sites (large academic institutions) to begin enrolling shortly. Terminated 1 low-performing legacy site.
- Compassionate use IDE discussions with a major institution for patients ineligible for heparin/citrate, capturing safety data for commercial support.

**【CFO Financial Update】**
- 2025 cash operating expenses reduced to $16-17M (from $17-19M), driven by $3.7M Q2 expenses (down 14% YoY). Cash balance $6.8M, with remaining financing tranches contingent on 17/35 patient milestones and stock price conditions.

**【Q&A Highlights】**
- Enrollment rate stability expected with new sites; 55 patients needed from September-December at 1.5 patients/site/month.
- Heparin/citrate shortages persist, heightening demand for nafamostat. Investors likely to waive stock price condition if milestones met.
- Site initiation confidence high due to pre-vetted institutions with internal timelines (3-4 months), 2 of 6 new sites already activated.

Talphera, Inc. (TLPH) Q2 2025 Earnings Call Transcript

- **Trial Acceleration**: FDA-approved 70-patient study size and 8 new sites (medical ICU, nephrologist-led) on track to complete trial by end-2025.
- **$14.8M Financing**: Pro forma cash of $9.8M supports operations through study completion; additional tranches tied to enrollment milestones.
- **Cost Efficiency**: Q1 2025 expenses down 31% YoY; full-year guidance cut to $17-19M.
- **Market Opportunity**: Niyad is the only FDA-approved regional anticoagulant for CRRT, addressing heparin/citrate shortages and off-label use.

**【CEO Opening Remarks】**
- **NEPHRO CRRT Trial Progress**: FDA approved a reduced study size (70 patients from 166) and activation of 3 new high-volume sites, with 5 more expected by mid-year. Focus on medical ICUs and nephrologist-led sites for efficient enrollment.
- **PIPE Financing**: Completed $14.8M commitment, with $4.925M received at closing and additional tranches tied to patient enrollment milestones (17, 35 patients) and stock price performance.
- **2025 Target**: Aim to complete trial by year-end, with Niyad approval targeted for 2026.

**【CFO Financial Update】**
- **Cash Position**: $5.4M as of Q1 2025, $9.8M pro forma post-April 2025 financing.
- **Cost Reduction**: Q1 2025 cash operating expenses ($2.9M) down 31% YoY, driven by personnel and G&A cuts. Full-year guidance revised to $17-19M from prior $20-22M range.
- **Financing Structure**: 3 equal tranches ($4.925M each) tied to enrollment and stock price milestones, expected to close later in 2025.

**【Q&A Key Points】**
- **Enrollment Activity**: Broader inclusion criteria increased screening activity at legacy and new sites, but legacy sites remain constrained by ICU type (surgical/cardiothoracic vs. medical). New sites (medical ICU, nephrologist-led) expected to drive enrollment growth.
- **Compassionate Use IDE**: Exploring IDE for patients with poor response to heparin/citrate, reflecting supply chain shortages and unmet need for FDA-approved regional anticoagulant.
- **Commercial Risk Mitigation**: Nafamostat's 30+ year safety track record in Japan/South Korea and lack of FDA-approved alternatives reduce commercial risk.

Talphera, Inc. (TLPH) Q1 2025 Earnings Call Transcript

- **FDA-Approved Study Streamlining**: 70-patient trial (90% power) with relaxed enrollment criteria to accelerate recruitment.
- **Site Expansion Momentum**: 8 active sites (70-100 CRRT/month) and 5+ pipeline sites for 2025 completion target.
- **$14.8M Financing**: Secured capital to complete study, with tranche milestones tied to enrollment and stock price.
- **Cost Efficiency**: 2025 expenses reduced to $18-19M, supporting disciplined cash management.

**【CEO Summary Section】**
- **NEPHRO CRRT Study Progress**: FDA approved reduction of study size from 166 to 70 patients, maintaining 90% power for primary endpoint. Two key protocol changes: removal of 48-hour CRRT exclusion and heparin intolerance documentation requirement.
- **Clinical Site Expansion**: 8 enrollment-ready sites (7 screening), targeting medical ICU and nephrologist-led teams. 5 additional sites expected by mid-2025, with higher CRRT volumes (90-100/month).
- **Private Placement Financing**: $14.8M gross proceeds (3 tranches), first tranche closing in April. Milestones: 17 and 35 patient enrollments, with stock price above $0.73.
- **FDA Alignment**: Breakthrough designation enables efficient regulatory engagement, with study completion targeted for end-2025.

**【CFO Financial Commentary】**
- **Q4 2024 Financials**: Combined R&D and SG&A expenses $3M (down 30% YoY). Cash balance $8.9M as of Dec 31, 2024.
- **2025 Guidance**: Operating expenses $18-19M, excluding stock-based compensation. Financing and cash position support study completion.

**【Q&A Key Points】**
- **Heparin Avoidance**: Institutions prefer regional anticoagulants due to heparin's systemic bleeding risk and titration complexity.
- **Site Activation Efficiency**: New sites activated in <4 months vs. >1 year for legacy sites. Productive sites average 20 CRRT patients/month.
- **Milestone Timing**: 17 patient enrollment milestone expected mid-2025, 35 patients by Q3 2025. No time limits on achievement.
- **Management Participation**: CEO Vince Angotti participating in private placement alongside Nantahala Capital and Rosalind Advisors.

Talphera (TLPH)-31 Mar 25-2024 Q4 Earnings call transcript

Talphera (TLPH)-13 Nov 24-2024 Q3 Earnings call transcript

Talphera (TLPH)-14 Aug 24-2024 Q2 Earnings call transcript

Talphera (TLPH)-14 May 24-2024 Q1 Earnings call transcript

Talphera (TLPH)-6 Mar 24-2023 Q4 Earnings call transcript

Acelrx Pharmaceuticals (ACRX)-8 Nov 23-2023 Q3 Earnings call transcript

Acelrx Pharmaceuticals (ACRX)-10 Aug 23-2023 Q2 Earnings call transcript

Acelrx Pharmaceuticals (ACRX)-10 May 23-2023 Q1 Earnings call transcript

Acelrx Pharmaceuticals (ACRX)-30 Mar 23-2022 Q4 Earnings call transcript

Acelrx Pharmaceuticals (ACRX)-15 Nov 22-2022 Q3 Earnings call transcript

Acelrx Pharmaceuticals (ACRX)-12 Aug 22-2022 Q2 Earnings call transcript

Acelrx Pharmaceuticals (ACRX)-16 May 22-2022 Q1 Earnings call transcript

Acelrx Pharmaceuticals (ACRX)-11 Mar 22-2021 Q4 Earnings call transcript

Acelrx Pharmaceuticals (ACRX)-15 Nov 21-2021 Q3 Earnings call transcript

Acelrx Pharmaceuticals (ACRX)-16 Aug 21-2021 Q2 Earnings call transcript

Acelrx Pharmaceuticals (ACRX)-18 May 21-2021 Q1 Earnings call transcript

Acelrx Pharmaceuticals (ACRX)-16 Mar 21-2020 Q4 Earnings call transcript

Acelrx Pharmaceuticals (ACRX)-5 Nov 20-2020 Q3 Earnings call transcript

Acelrx Pharmaceuticals (ACRX)-10 Aug 20-2020 Q2 Earnings call transcript

Acelrx Pharmaceuticals (ACRX)-11 May 20-2020 Q1 Earnings call transcript

Acelrx Pharmaceuticals (ACRX)-16 Mar 20-2019 Q4 Earnings call transcript

Acelrx Pharmaceuticals (ACRX)-6 Nov 19-2019 Q3 Earnings call transcript

Acelrx Pharmaceuticals (ACRX)-5 Aug 19-2019 Q2 Earnings call transcript

Acelrx Pharmaceuticals (ACRX)-9 May 19-2019 Q1 Earnings call transcript

Acelrx Pharmaceuticals (ACRX)-7 Mar 19-2018 Q4 Earnings call transcript

Acelrx Pharmaceuticals (ACRX)-5 Nov 18-2018 Q3 Earnings call transcript

Acelrx Pharmaceuticals (ACRX)-2 Aug 18-2018 Q2 Earnings call transcript

Acelrx Pharmaceuticals (ACRX)-9 May 18-2018 Q1 Earnings call transcript

Acelrx Pharmaceuticals (ACRX)-8 Mar 18-2017 Q4 Earnings call transcript

Acelrx Pharmaceuticals (ACRX)-9 Nov 17-2017 Q3 Earnings call transcript

Actual											-4	-1.6	-2	-2	-1.6	-1.6	-1.4	-1.2	-1.2	9.6	-0.94	-1	-0.75	-0.41	-0.08	-0.25	-0.16	-0.15	-0.13	-0.07	-0.1	-0.1	-0.11
Forecast											-3.35	-2.6	-1.65	-2.0667	-1.6667	-1.6	-1.4	-1.3	-1.2	-1.5	-1.2	-0.51	-0.785	-0.53	-0.28	-0.2	-0.25	-0.2133	-0.19	-0.165	-0.1433	-0.13	-0.125
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-19.40%	+38.46%	-21.21%	+3.23%	+4.00%	0.00%	0.00%	+7.69%	0.00%	+740.00%	+21.67%	-96.08%	+4.46%	+22.64%	+71.43%	-25.00%	+36.00%	+29.68%	+31.58%	+57.58%	+30.22%	+23.08%	+12.00%

Actual	--	--	--	--	--	--	--	--	--	--	386.00K	2.92M	1.37M	738.00K	511.00K	443.00K	1.86M	2.00K	442.00K	570.00K	507.00K	252.00K	--	300.00K	117.00K	281.00K	0	0	0	0	27.00K	0	1.00K
Forecast	--	--	--	--	--	--	--	--	--	--	1.97M	2.02M	2.83M	1.74M	1.06M	625.00K	1.90M	1.85M	550.00K	550.00K	625.00K	4.50M	1.65M	75.00K	263.00K	281.00K	0	0	0	0	0	0	0
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-80.37%	+44.47%	-51.74%	-57.64%	-51.70%	-29.12%	-2.00%	-99.89%	-19.64%	+3.64%	-18.88%	-94.40%	0.00%	+300.00%	-55.51%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

TLPH

TLPH fundamentals

TLPH Q3 2025 Earnings

Earnings Call

You can ask Aime

TLPH

TLPH fundamentals

TLPH Q3 2025 Earnings

Earnings Call

TLPH Earnings Call Summary for Q3/20254:30 PM on Nov 12, 2025

TLPH Earnings Call Summary for Q2/20254:30 PM on Aug 14, 2025

TLPH Earnings Call Summary for Q1/20254:30 PM on May 14, 2025

TLPH Earnings Call Summary for Q4/20244:30 PM on Mar 31, 2025

TLPH Earnings Call Summary for Q3/20244:30 PM on Nov 13, 2024

You can ask Aime